RusnanoMedInvest specializes in investing in the development of innovative pharmaceutical technologies and products in Russia and worldwide.
We are interested in investment opportunities in promising new developments in the field of pharmaceuticals and medical equipment;
Our investment strategy and focus centers primarily around projects at the later stages of development, in particular compounds or products that have proven, market-relevant differentiated therapeutic efficacy, tolerability or safety in phase 2 or later or otherwise demonstrate game-changing potential with respect to patient welfare or healthcare economics.
Our portfolio companies:
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 90,000 shares of its common stock to two new employees, with a grant date of June 14, 2018 .
14 June 2018
31 May 2018
30 May 2018